Across TCGA pan-cancer cohorts, VPS13D mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of VPS13D’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where VPS13D mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types VPS13D is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.
CCRCC, LSCC, and LUAD are the cancer types where VPS13D tumor–normal differential expression is most reproducible.